NRC-AN-019

CAS : 879507-25-2

Ref. 3D-EKB50725

Informations sur le produit

• Nom: NRC-AN-019
• Marque: Biosynth
• Description: NRC-AN-019 is an imatinib-resistant drug that belongs to the class of bcr-abl inhibitors. It has been shown to be effective in women with metastatic breast cancer and who are resistant to lapatinib and imatinib. NRC-AN-019 is a polymeric matrix that contains epidermal growth factor (EGF) and is designed for topical administration. The drug binds to the receptor tyrosine kinase erbB2, which prevents it from binding with the epidermal growth factor receptor (EGFR). This leads to suppression of cellular proliferation, differentiation, and angiogenesis. NRC-AN-019 also has pharmacokinetic properties that allow for escalation of dosage without significant toxicities or side effects.

Propriétés chimiques

• Masse moléculaire: 517.4 g/mol
• Formule: C₂₅H₁₇F₆N₅O
• Degré de pureté: Min. 95%